Cargando…

Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening

Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that >300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of symptoms, such as muscle and joint pain, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pothineni, Venkata Raveendra, Wagh, Dhananjay, Babar, Mustafeez Mujtaba, Inayathullah, Mohammed, Solow-Cordero, David, Kim, Kwang-Min, Samineni, Aneesh V, Parekh, Mansi B, Tayebi, Lobat, Rajadas, Jayakumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827596/
https://www.ncbi.nlm.nih.gov/pubmed/27103785
http://dx.doi.org/10.2147/DDDT.S101486
_version_ 1782426489762873344
author Pothineni, Venkata Raveendra
Wagh, Dhananjay
Babar, Mustafeez Mujtaba
Inayathullah, Mohammed
Solow-Cordero, David
Kim, Kwang-Min
Samineni, Aneesh V
Parekh, Mansi B
Tayebi, Lobat
Rajadas, Jayakumar
author_facet Pothineni, Venkata Raveendra
Wagh, Dhananjay
Babar, Mustafeez Mujtaba
Inayathullah, Mohammed
Solow-Cordero, David
Kim, Kwang-Min
Samineni, Aneesh V
Parekh, Mansi B
Tayebi, Lobat
Rajadas, Jayakumar
author_sort Pothineni, Venkata Raveendra
collection PubMed
description Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that >300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of symptoms, such as muscle and joint pain, psychosocial and cognitive difficulties, and generalized fatigue. This condition is referred to as posttreatment Lyme disease syndrome. While there is no evidence for the presence of viable infectious organisms in individuals with posttreatment Lyme disease syndrome, some researchers found surviving Borrelia burgdorferi population in rodents and primates even after antibiotic treatment. Although such observations need more ratification, there is unmet need for developing the therapeutic agents that focus on removing the persisting bacterial form of B. burgdorferi in rodent and nonhuman primates. For this purpose, high-throughput screening was done using BacTiter-Glo assay for four compound libraries to identify candidates that stop the growth of B. burgdorferi in vitro. The four chemical libraries containing 4,366 compounds (80% Food and Drug Administration [FDA] approved) that were screened are Library of Pharmacologically Active Compounds (LOPAC1280), the National Institutes of Health Clinical Collection, the Microsource Spectrum, and the Biomol FDA. We subsequently identified 150 unique compounds, which inhibited >90% of B. burgdorferi growth at a concentration of <25 µM. These 150 unique compounds comprise many safe antibiotics, chemical compounds, and also small molecules from plant sources. Of the 150 unique compounds, 101 compounds are FDA approved. We selected the top 20 FDA-approved molecules based on safety and potency and studied their minimum inhibitory concentration and minimum bactericidal concentration. The promising safe FDA-approved candidates that show low minimum inhibitory concentration and minimum bactericidal concentration values can be chosen as lead molecules for further advanced studies.
format Online
Article
Text
id pubmed-4827596
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48275962016-04-21 Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening Pothineni, Venkata Raveendra Wagh, Dhananjay Babar, Mustafeez Mujtaba Inayathullah, Mohammed Solow-Cordero, David Kim, Kwang-Min Samineni, Aneesh V Parekh, Mansi B Tayebi, Lobat Rajadas, Jayakumar Drug Des Devel Ther Original Research Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that >300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of symptoms, such as muscle and joint pain, psychosocial and cognitive difficulties, and generalized fatigue. This condition is referred to as posttreatment Lyme disease syndrome. While there is no evidence for the presence of viable infectious organisms in individuals with posttreatment Lyme disease syndrome, some researchers found surviving Borrelia burgdorferi population in rodents and primates even after antibiotic treatment. Although such observations need more ratification, there is unmet need for developing the therapeutic agents that focus on removing the persisting bacterial form of B. burgdorferi in rodent and nonhuman primates. For this purpose, high-throughput screening was done using BacTiter-Glo assay for four compound libraries to identify candidates that stop the growth of B. burgdorferi in vitro. The four chemical libraries containing 4,366 compounds (80% Food and Drug Administration [FDA] approved) that were screened are Library of Pharmacologically Active Compounds (LOPAC1280), the National Institutes of Health Clinical Collection, the Microsource Spectrum, and the Biomol FDA. We subsequently identified 150 unique compounds, which inhibited >90% of B. burgdorferi growth at a concentration of <25 µM. These 150 unique compounds comprise many safe antibiotics, chemical compounds, and also small molecules from plant sources. Of the 150 unique compounds, 101 compounds are FDA approved. We selected the top 20 FDA-approved molecules based on safety and potency and studied their minimum inhibitory concentration and minimum bactericidal concentration. The promising safe FDA-approved candidates that show low minimum inhibitory concentration and minimum bactericidal concentration values can be chosen as lead molecules for further advanced studies. Dove Medical Press 2016-04-01 /pmc/articles/PMC4827596/ /pubmed/27103785 http://dx.doi.org/10.2147/DDDT.S101486 Text en © 2016 Pothineni et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Pothineni, Venkata Raveendra
Wagh, Dhananjay
Babar, Mustafeez Mujtaba
Inayathullah, Mohammed
Solow-Cordero, David
Kim, Kwang-Min
Samineni, Aneesh V
Parekh, Mansi B
Tayebi, Lobat
Rajadas, Jayakumar
Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening
title Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening
title_full Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening
title_fullStr Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening
title_full_unstemmed Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening
title_short Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening
title_sort identification of new drug candidates against borrelia burgdorferi using high-throughput screening
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827596/
https://www.ncbi.nlm.nih.gov/pubmed/27103785
http://dx.doi.org/10.2147/DDDT.S101486
work_keys_str_mv AT pothinenivenkataraveendra identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening
AT waghdhananjay identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening
AT babarmustafeezmujtaba identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening
AT inayathullahmohammed identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening
AT solowcorderodavid identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening
AT kimkwangmin identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening
AT saminenianeeshv identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening
AT parekhmansib identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening
AT tayebilobat identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening
AT rajadasjayakumar identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening